Goldman Sachs
GYRE icon

Goldman Sachs’s Gyre Therapeutics GYRE Stock Holding History

Goldman Sachs’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-226
Closed -$737K – 6823
2013
Q4 		$737K Buy
226
+93
+70% +$367K ﹤0.01% 5001
2013
Q3 		$558K Buy
133
+46
+53% +$185K ﹤0.01% 5086
2013
Q2 		$293K Buy
+87
New +$331K ﹤0.01% 5335

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Goldman Sachs's GYRE Position: Q2 2026 in Review

Goldman Sachs increased its Gyre Therapeutics (GYRE) stake by 18% in Q2 2026, buying an estimated $89.3K and bringing the position to 86,235 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #5618.

Goldman Sachs first reported a position in GYRE in Q2 2013 and has held it in 43 quarters since. The position peaked at $1.7M in Q4 2020. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Goldman Sachs held 86,235 shares of Gyre Therapeutics worth $568K as of Q2 2026.
  • Goldman Sachs bought 13,113 Gyre Therapeutics shares in Q2 2026, an estimated $89.3K.
  • Gyre Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5618 holding.
  • Goldman Sachs first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 43 quarters since.
  • Goldman Sachs's Gyre Therapeutics position peaked at $1.7M in Q4 2020.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.